Literature DB >> 30843759

Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations.

Jianzhong Chen1, Laixue Pang1, Wei Wang1, Lifei Wang1, John Z H Zhang2,3, Tong Zhu2,3.   

Abstract

CDK2 can be used as an attractive target for development of efficient inhibitors curing multiple disease relating with CDK2. In this work, molecular dynamics (MD) simulations and binding free energy calculations were coupled to probe conformational changes of CDK2 due to inhibitor associations and binding mechanisms of inhibitors PM1, FMD and X64 to CDK2. The results suggest that the binding strength of FMD and X64 to CDK2 is stronger than that of PM1. Principal component (PC) analysis and cross-correlation map calculations based on the equilibrated MD trajectories demonstrate that the structural difference in inhibitors exerts important impact on motion modes and dynamics behavior of CDK2. Residue-based free energy decomposition method was adopted to estimate the inhibitor-residue spectrum. The results not only efficiently identify the hot interaction spot of inhibitors with CDK2 but also show that the hydrophobic rings R1, R2 and R3 as well as polar groups of three inhibitors play key roles in favorably binding of inhibitors to CDK2. This work is expected to contribute energetic basis and dynamics information to development of promising inhibitors toward CDK2.Communicated by Ramaswamy H. Sarma.

Entities:  

Keywords:  CDK2; MM-GBSA; conformational changes; molecular dynamics simulations; principal component analysis

Year:  2019        PMID: 30843759     DOI: 10.1080/07391102.2019.1591304

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  5 in total

1.  Discovery of pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as novel CDK2 inhibitors: synthesis, biological and molecular modeling investigations.

Authors:  Ibrahim F Nassar; Mohammed T Abdel Aal; Wael A El-Sayed; Mahmoud A E Shahin; Elsayed G E Elsakka; Mahmoud Mohamed Mokhtar; Maghawry Hegazy; Mohamed Hagras; Asmaa A Mandour; Nasser S M Ismail
Journal:  RSC Adv       Date:  2022-05-17       Impact factor: 4.036

2.  Synthesis, biological evaluation, and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold with apoptotic activity.

Authors:  Asmaa A Mandour; Ibrahim F Nassar; Mohammed T Abdel Aal; Mahmoud A E Shahin; Wael A El-Sayed; Maghawry Hegazy; Amr Mohamed Yehia; Ahmed Ismail; Mohamed Hagras; Eslam B Elkaeed; Hanan M Refaat; Nasser S M Ismail
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

3.  Free energy calculations of ALS-causing SOD1 mutants reveal common perturbations to stability and dynamics along the maturation pathway.

Authors:  Nicholas G M Wells; Grant A Tillinghast; Alison L O'Neil; Colin A Smith
Journal:  Protein Sci       Date:  2021-06-22       Impact factor: 6.993

4.  A Novel lncRNA ENST00000512916 Facilitates Cell Proliferation, Migration and Cell Cycle Progression in Ameloblastoma.

Authors:  Yan Sun; Xing Niu; Guannan Wang; Xue Qiao; Lijie Chen; Ming Zhong
Journal:  Onco Targets Ther       Date:  2020-02-19       Impact factor: 4.147

5.  Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.

Authors:  Adel A-H Abdel-Rahman; Amira K F Shaban; Ibrahim F Nassar; Dina S El-Kady; Nasser S M Ismail; Samy F Mahmoud; Hanem M Awad; Wael A El-Sayed
Journal:  Molecules       Date:  2021-06-26       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.